Intuitive Surgical delivered a decisive beat. Non-GAAP earnings were $3.00 per share, 13.2% above the $2.61 consensus and comfortably ahead of the $2.65 Earnings Whisper number. Revenue of $3.049 billion topped the $2.88 billion estimate by 5.9%. Earnings grew 26.6% year over year and revenue grew 21.7%. Revenue growth accelerated from 19% in the second quarter, and non-GAAP EPS stepped up from $2.80 sequentially. The headline, however, is driven mostly by capital equipment. The recurring, procedure-based side of the model is slowing at the margin and now faces a quantified pricing headwind. That is the central tension.

The quality of the beat holds up reasonably well. Non-GAAP EPS included a $0.06 benefit from IEEPA tariff refunds. Even without it, results cleared consensus by a wide margin. Two other factors flattered the per-share comparison:

- **Buybacks:** The company repurchased 7.8 million shares for $2.94 billion, and diluted shares fell to 351.6 million from 361.8 million a year ago.

- **Operating leverage:** Non-GAAP operating income rose to $1.27 billion from $976 million, a margin of roughly 42%. Non-GAAP gross margin was 69.9%, or 68.9% excluding the tariff refund, up about 90 basis points year over year.

On a GAAP basis, EPS fell to $1.49 from $1.95. The decline reflects a $450 million pre-tax charge to settle the da Vinci antitrust class action, about $0.99 per share after tax. Management characterized the settlement as no-fault. It removes a long-running overhang, but it still requires preliminary and final court approval, so the overhang is not fully gone yet.

Beneath the headline, the mix tells two different stories.

- **Systems:** Systems revenue jumped to $769 million from $590 million on a record 546 da Vinci placements, up 28%. That compares with 18% growth in Q2 and 17% in Q1. Net placements rose 40%, da Vinci 5 accounted for 315 units, and single-port reached a record 42 systems. Operating leases made up 291 placements, 160 of them usage-based, so part of this capital strength converts to revenue over time rather than upfront.

- **Procedures:** Instruments and accessories grew a solid 18%, but worldwide da Vinci procedure growth eased to 14% from 15% in Q2 and 16% in Q1. U.S. da Vinci procedures grew just 10%, down from 12% and 14% earlier in the year and the slowest pace since COVID. Management pointed to a tough 16% comparison, and Ion procedures grew a healthy 31%.

- **Guidance:** The full-year da Vinci procedure range was narrowed to 14% to 15%, with the company expecting to land near the midpoint. That effectively reaffirms rather than raises the outlook.

The newly quantified risks are what bears will focus on. Management expects instrument and accessory revenue per procedure to decline roughly 3% to 5%, on a mix-constant basis, once fully implemented through 2027. Two sources drive this:

- an EUP 2.0 volume-based pricing program aimed at high-volume benign procedures;

- China charge-code cuts that begin in November.

The bet is elasticity, meaning lower pricing should broaden adoption. The offsets management cited, including force feedback, single-port, and da Vinci 5 insufflation, are still early. Force feedback is used in only about 8% of da Vinci 5 cases.

Management also flagged several U.S. policy headwinds:

- ACA enrollment changes;

- Medicaid eligibility changes;

- potential 340B changes.

It signaled willingness to reinvest operating margin above a 35% to 40% range into 2027 spending. Cash fell to $6.8 billion after the buyback, and other income guidance was trimmed to $300 million to $310 million.

The call still preserved a credible growth story. Non-GAAP gross margin guidance rose for a third straight quarter, to 68.7% to 69.3%. The cardiac line-of-sight opportunity was lifted to 300,000 to 400,000 procedures annually from roughly 160,000. Other developments included:

- ambulatory surgery center placements over the past two quarters exceeding nearly three prior years combined;

- international placements up 29%;

- India procedures up 42%;

- a GI flexible endoscope clearance and the Benign COMPARE meta-analysis, which add pipeline and clinical support.

Investor sentiment improved meaningfully, rising from -0.33 at the prior report to -0.13. It remains negative, which suggests skepticism has eased but not disappeared. The stock has gained 20% since opening at $365.02 after the July report and now sits at $438, essentially on its 200-day moving average of $438.96. Shares have recovered substantially but have not reclaimed clear technical footing. Among the trend readings, AVWAP is positive while price trend is neutral, consistent with a recovery that is still being tested.

The bottom line is that Intuitive beat expectations on accelerating capital placements, expanding margins, and buyback-aided EPS. Growth in its core procedure engine is slowing in the U.S., and management has now put a number on the pricing it will sacrifice to reignite adoption. The settlement and margin guidance strengthen the setup. Whether this quarter marks durable improvement depends on procedure growth stabilizing as EUP and China pricing take hold in 2027.